- Home
- PDM vs GHRS Comparison
PDM vs GHRS Comparison
Compare PDM & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDM | GHRS |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PDM | GHRS |
|---|---|---|
| Price | $7.58 | $15.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.00 | ★ $39.75 |
| AVG Volume (30 Days) | ★ 856.7K | 172.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,994,000.00 | N/A |
| Revenue This Year | $0.91 | N/A |
| Revenue Next Year | $3.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.46 | $7.98 |
| 52 Week High | $9.19 | $19.51 |
Technical Indicators
Market Signals| Indicator | PDM | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 53.36 |
| Support Level | $7.17 | $11.84 |
| Resistance Level | $7.83 | $16.24 |
| Average True Range (ATR) | 0.34 | 0.84 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 19.17 | 70.67 |
Price Performance
Historical ComparisonAbout PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.